Cushing's Syndrome

1. Clinical Overview

Summary

Cushing's Syndrome refers to the clinical phenotype caused by chronic glucocorticoid (cortisol) excess. The nomenclature is clinically important: Cushing's Syndrome encompasses all causes of hypercortisolism, while Cushing's Disease specifically denotes ACTH-secreting pituitary adenomas. [1,2]

The most common cause worldwide is iatrogenic (exogenous glucocorticoid therapy), seen in patients receiving chronic corticosteroid treatment for inflammatory, autoimmune, or malignant conditions. Endogenous Cushing's syndrome has an estimated incidence of 0.7-2.4 per million per year, making it a rare but significant endocrine disorder. [3,4]

Endogenous causes are classified by ACTH-dependence:

• ACTH-Dependent (80-85%): Pituitary adenomas (Cushing's Disease, 70%), ectopic ACTH secretion (10-15%)
• ACTH-Independent (15-20%): Adrenal adenomas, adrenal carcinomas, bilateral adrenal hyperplasia [1,5]

The syndrome presents as a multisystem disorder characterized by centripetal obesity, moon facies, proximal myopathy, skin fragility with easy bruising, glucose intolerance or diabetes, hypertension, and increased susceptibility to infections. Untreated Cushing's syndrome carries significant morbidity and mortality, with standardized mortality ratios ranging from 1.8 to 4.8 depending on etiology. [6,7]

Clinical Pearls

Syndrome vs Disease: This is the most common examination trap.

• Cushing's Syndrome: Any cause of cortisol excess (exogenous steroids, adrenal tumor, pituitary tumor, ectopic ACTH)
• Cushing's Disease: Specifically a pituitary adenoma secreting ACTH (most common endogenous cause)

The "Ectopic" Phenotype: Ectopic ACTH secretion (typically from small cell lung cancer, bronchial carcinoids, or neuroendocrine tumors) presents with rapid onset and aggressive features. These patients often lack classic Cushingoid appearance (moon face, buffalo hump) due to rapid disease progression. Instead, they present with:

• Profound muscle wasting and cachexia
• Severe hypokalaemia (K+ less than 2.5 mmol/L) with metabolic alkalosis
• Hyperpigmentation (melanocyte-stimulating hormone [MSH] effect from high ACTH)
• Rapid onset (weeks to months vs. years for pituitary disease) [8,9]

Pseudo-Cushing's States: Several physiological conditions mimic true Cushing's syndrome biochemically and clinically:

• Alcohol-related pseudo-Cushing's: Resolves within 2-4 weeks of abstinence
• Severe depression: Major depressive disorder with HPA axis activation
• Obesity: Simple obesity with insulin resistance
• Polycystic ovary syndrome (PCOS): Androgen excess with some overlapping features The insulin tolerance test or CRH stimulation test can help differentiate these conditions from true Cushing's. [10,11]

---

2. Epidemiology

Incidence and Prevalence

Endogenous Cushing's syndrome is rare:

• Incidence: 0.7-2.4 cases per million population per year [3,4]
• Prevalence: Approximately 40 cases per million population
• Iatrogenic Cushing's: Far more common, affecting an estimated 1-2% of the general population receiving chronic glucocorticoid therapy [12]

Demographics

Age Distribution:

• Cushing's Disease (pituitary): Peak incidence 20-50 years
• Adrenal adenomas: Peak incidence 30-50 years
• Ectopic ACTH: Peak incidence 40-60 years (reflecting underlying malignancy epidemiology)

Gender:

• Overall female predominance: Female-to-male ratio 3-5:1
• Cushing's Disease: Strong female predominance (F:M = 5-8:1)
• Adrenal adenomas: Female predominance (F:M = 4:1)
• Ectopic ACTH syndrome: Equal gender distribution or slight male predominance (reflecting lung cancer epidemiology) [4,13]

Etiology Distribution

Among endogenous cases:

• Cushing's Disease (pituitary adenoma): 60-70%
• Ectopic ACTH syndrome: 10-15%
• Adrenal adenoma: 10-15%
• Adrenal carcinoma: 5-10%
• Bilateral adrenal hyperplasia: less than 1%
• Cyclic Cushing's: 1-5% (intermittent hypercortisolism) [1,14]

---

3. Pathophysiology

Normal Hypothalamic-Pituitary-Adrenal (HPA) Axis

The HPA axis functions as a tightly regulated negative feedback system:

1. Hypothalamus secretes corticotropin-releasing hormone (CRH) and arginine vasopressin (AVP)
2. Anterior pituitary responds by secreting ACTH (cleaved from pro-opiomelanocortin [POMC])
3. Adrenal cortex (zona fasciculata) synthesizes and secretes cortisol
4. Negative feedback: Cortisol suppresses both CRH and ACTH secretion

Cortisol exhibits circadian rhythm with peak levels at 08:00-09:00 and nadir at midnight. This diurnal variation is lost in Cushing's syndrome. [15]

Molecular Pathophysiology

Cushing's Disease (Pituitary Adenomas):

• Monoclonal tumors arising from corticotroph cells
• Genetic alterations identified in 30-40%:
  • "USP8 mutations (ubiquitin-specific protease 8): Found in 35-60% of corticotroph adenomas, resulting in increased EGFR signaling and ACTH hypersecretion [16]"
  • "TP53 mutations: Associated with more aggressive tumors"
  • "BRAF mutations: Rare but identified in some cases"
• Most pituitary adenomas are microadenomas (less than 10 mm), with only 10-15% being macroadenomas (≥10 mm) [17]
• Tumors retain partial responsiveness to negative feedback (suppression with high-dose dexamethasone)

Ectopic ACTH Syndrome:

• Most common sources:
  • Small cell lung cancer (50-60%)
  • Bronchial carcinoid tumors (10-15%)
  • Thymic carcinoids (5-10%)
  • Pancreatic neuroendocrine tumors (5-10%)
  • Pheochromocytomas (rare)
• Tumors produce ACTH autonomously with complete loss of regulatory feedback
• High ACTH levels overwhelm cortisol's negative feedback
• Co-secretion of CRH may occur in some cases [8,9]

Adrenal Causes:

• Adenomas: Benign tumors typically 2-5 cm, producing cortisol autonomously
• Carcinomas: Larger tumors (> 6 cm average), often with local invasion or metastases, may produce multiple steroids (cortisol, androgens, aldosterone)
• Genetic syndromes associated with adrenal tumors:
  • "PRKAR1A mutations: Carney complex (pigmented skin lesions, cardiac myxomas, primary pigmented nodular adrenocortical disease)"
  • "APC mutations: Familial adenomatous polyposis"
  • "MEN1 mutations: Multiple endocrine neoplasia type 1 [18]"

Cortisol Effects by System

Metabolic:

• Gluconeogenesis: Stimulates hepatic glucose production → hyperglycemia
• Lipolysis: Increased visceral fat, reduced peripheral fat → centripetal obesity
• Proteolysis: Muscle and skin protein breakdown → proximal myopathy, skin thinning

Cardiovascular:

• Mineralocorticoid effects: Cortisol activates mineralocorticoid receptors → sodium retention, potassium wasting, hypertension
• Vascular effects: Increased vascular sensitivity to catecholamines
• Thrombogenic: Hypercoagulable state with increased VTE risk [19]

Skeletal:

• Osteoblast inhibition: Reduced bone formation
• Osteoclast activation: Increased bone resorption
• Calcium absorption: Decreased intestinal calcium absorption
• Result: Rapid-onset osteoporosis with vertebral fractures [20]

Immunologic:

• Anti-inflammatory: Reduced cytokine production, impaired T-cell function
• Infection susceptibility: Increased risk of bacterial, fungal, and opportunistic infections

Dermatologic:

• Collagen breakdown: Skin thinning, striae formation, easy bruising
• Wound healing: Impaired tissue repair

---

4. Classification and Differential Diagnosis

Etiological Classification

Clinical Differentiation

Cushing's Disease vs. Ectopic ACTH:

Pseudo-Cushing's States

Conditions that can mimic Cushing's syndrome biochemically and/or clinically:

1. Alcohol-Related Pseudo-Cushing's:

   • Mechanism: Alcohol stimulates HPA axis
   • Features: Elevated UFC, loss of circadian rhythm, physical stigmata
   • Diagnosis: Resolves with 2-4 weeks abstinence; normal CRH stimulation test [10]

2. Depression-Related Pseudo-Cushing's:

   • Mechanism: HPA axis activation in severe depression
   • Features: Elevated cortisol, physical overlap minimal
   • Diagnosis: Combined dexamethasone-CRH test can differentiate [11]

3. Physiologic States:

   • Pregnancy (elevated cortisol-binding globulin)
   • Obesity (increased cortisol production rate with normal free cortisol)
   • Chronic stress or severe illness

4. Medications:

   • Estrogen therapy (increases cortisol-binding globulin)
   • Anticonvulsants (phenytoin, carbamazepine - induce cortisol metabolism)

---

5. Clinical Presentation

Physical Examination Findings

Facial and Head:

• Moon facies (90%): Round, plethoric face with loss of normal contours
• Facial plethora (84%): Redness of cheeks, often misattributed to rosacea
• Supraclavicular fat pads (60%): Characteristic "cushions" above clavicles
• Dorsocervical fat pad ("buffalo hump", 46%): Fat accumulation at C7-T1 level
• Temporal wasting: Hollowing of temporal fossae (advanced cases)

Skin and Soft Tissue:

• Wide purple striae (60-70%): > 1 cm width, violaceous (NOT the pale striae of simple obesity or pregnancy)
  • "Common locations: Abdomen, flanks, axillae, thighs, breasts"
• Easy bruising (40-60%): Spontaneous ecchymoses on minimal trauma
• Skin thinning: Translucent skin with visible veins
• Acne (30%): Particularly facial and truncal
• Hirsutism (64% in women): Androgen excess from adrenal source
• Hyperpigmentation: Only in ACTH-dependent causes (ectopic > pituitary)
• Poor wound healing: Delayed healing of minor cuts and surgical incisions

Body Habitus:

• Central (truncal) obesity (95%): Fat deposition in face, neck, trunk, abdomen
• Peripheral muscle wasting (70%): Thin extremities - "lemon on sticks" appearance
• Proximal myopathy (60-70%): Difficulty:
  • Rising from sitting position without using arms
  • Climbing stairs
  • Combing hair or reaching overhead shelves

Musculoskeletal:

• Osteoporosis: Present in up to 50% at diagnosis
• Vertebral compression fractures (30-50%): Often asymptomatic
• Avascular necrosis: Particularly femoral and humeral heads
• Back pain: Due to vertebral fractures or muscle weakness

Systemic Manifestations

Cardiovascular (80% have ≥1 feature):

• Hypertension (75-85%): Often resistant to standard therapy
• Left ventricular hypertrophy: From chronic hypertension
• Accelerated atherosclerosis: Increased cardiovascular events
• Cardiomyopathy: In severe or prolonged cases [21]

Metabolic and Endocrine:

• Impaired glucose tolerance (40-45%)
• Diabetes mellitus (20-47%): Often requires insulin
• Dyslipidemia (70%): Elevated triglycerides, reduced HDL
• Hyperuricemia: Gout may occur
• Gonadal dysfunction:
  • "Women: Oligomenorrhea, amenorrhea (75%), reduced fertility"
  • "Men: Erectile dysfunction, reduced libido, gynecomastia (from androgen conversion)"

Psychiatric and Neurological (50-70%):

• Depression (50-60%): Can be severe, may include suicidal ideation
• Anxiety disorders (40%)
• Emotional lability: Mood swings, irritability
• Cognitive impairment: Memory problems, reduced concentration
• Psychosis (5-10%): Hallucinations, delusions (medical emergency)
• Insomnia: Sleep disturbance common

Immunologic:

• Increased infection susceptibility: Bacterial (pneumonia, UTI), fungal (candidiasis, aspergillosis), opportunistic (Pneumocystis jirovecii)
• Impaired vaccine responses

Ophthalmologic:

• Visual field defects: From pituitary macroadenomas compressing optic chiasm
• Exophthalmos: Rare, from retro-orbital fat accumulation
• Cataracts: Posterior subcapsular cataracts
• Glaucoma: Increased intraocular pressure

Renal:

• Nephrolithiasis (15-20%): Calcium oxalate stones from hypercalciuria

Hematologic:

• Erythrocytosis: Mild polycythemia
• Leukocytosis: Neutrophilia with lymphopenia
• Thrombocytosis: Increased platelet count
• Hypercoagulability: 2-3 fold increased VTE risk [19]

Special Populations

Pediatric Cushing's Syndrome:

• Growth failure: Most specific finding in children
• Weight gain with growth deceleration: Key diagnostic clue
• Delayed puberty: Gonadotropin suppression
• Causes differ from adults: Higher proportion of adrenal carcinomas (50% of adrenal causes)

Cyclic Cushing's Syndrome:

• Intermittent cortisol secretion with symptom-free intervals
• Diagnosis requires prolonged monitoring (multiple 24-hour UFC collections)
• Cycles range from days to months [14]

---

6. Investigations

The diagnostic approach follows a three-tier strategy: (1) Establish hypercortisolism, (2) Determine ACTH-dependence, (3) Localize the source. [1,2]

Tier 1: Screening for Hypercortisolism

Screening is indicated when multiple features of Cushing's syndrome are present, particularly discriminatory findings:

• Easy bruising
• Facial plethora
• Proximal myopathy
• Wide (> 1 cm) purple striae
• Children with weight gain AND growth deceleration

At least TWO of THREE tests should be abnormal to establish hypercortisolism:

1. 24-Hour Urinary Free Cortisol (UFC):

• Principle: Measures unbound cortisol excreted in urine over 24 hours
• Normal: less than 250 nmol/24h (varies by assay)
• Cushing's syndrome: > 3-4× upper limit of normal (ULN)
• Interpretation:
  • Values 1-3× ULN may occur in pseudo-Cushing's states
  • At least 2 elevated collections recommended
  • "False positives: High fluid intake (> 5 L/day)"
  • "False negatives: Renal impairment (GFR less than 60 mL/min) [22]"

2. Late-Night Salivary Cortisol (LNSC):

• Principle: Loss of circadian rhythm is an early, sensitive sign of Cushing's
• Collection: Saliva sample at 23:00-24:00 (bedtime)
• Normal: less than 3.6-5.5 nmol/L (assay-dependent)
• Cushing's syndrome: Elevated (> 2× ULN)
• Advantages: Non-invasive, home collection, not affected by stress
• Interpretation: At least 2 elevated samples recommended
• Pitfalls: Tobacco use, licorice ingestion can elevate results [23]

3. Overnight Dexamethasone Suppression Test (ONDST):

• Protocol:
  • "Administer 1 mg dexamethasone orally at 23:00-24:00"
  • "Measure serum cortisol at 08:00-09:00 next morning"
• Normal: Cortisol less than 50 nmol/L (1.8 μg/dL)
• Cushing's syndrome: Cortisol > 50 nmol/L
• Interpretation:
  • "Gray zone: 50-140 nmol/L (consider repeating or use alternative test)"
  • Very high values (> 500 nmol/L) strongly suggest Cushing's
• False positives:
  • Medications inducing CYP3A4 (phenytoin, carbamazepine, rifampin) - accelerate dexamethasone metabolism
  • Estrogen therapy - increases cortisol-binding globulin
  • Pseudo-Cushing's states
• Alternative: Low-dose DST (0.5 mg q6h × 48h) has similar performance [1,2]

Tier 2: ACTH-Dependent vs. ACTH-Independent

Once hypercortisolism is confirmed, measure plasma ACTH at 08:00-09:00:

Interpretation:

• Suppressed (less than 1.1 pmol/L or less than 5 pg/mL): ACTH-independent → Adrenal source
  • Proceed to adrenal CT/MRI
• Normal or elevated (> 2.2 pmol/L or > 10 pg/mL): ACTH-dependent → Pituitary or ectopic
  • Proceed to Tier 3 testing
• Very high (> 20 pmol/L or > 100 pg/mL): Strongly suggests ectopic ACTH [24]

Technical considerations:

• Sample must be collected in EDTA tube, kept on ice, separated and frozen rapidly
• Assays can be problematic; two-site immunometric assays preferred
• Consider checking multiple samples due to pulsatile secretion

Tier 3: Localizing ACTH Source (Pituitary vs. Ectopic)

A. High-Dose Dexamethasone Suppression Test (HDDST):

• Protocol:
  • "Classic: 2 mg dexamethasone q6h × 48 hours (8 mg/day)"
  • "Overnight variant: 8 mg dexamethasone at 23:00, cortisol at 08:00"
• Interpretation:
  • > 50% suppression from baseline → Cushing's Disease (pituitary)
  • less than 50% suppression → Ectopic ACTH or (rarely) pituitary
• Performance:
  • "Sensitivity for pituitary: 60-80%"
  • "Specificity: 60-100%"
  • 10-20% of pituitary adenomas fail to suppress [1]

B. CRH Stimulation Test:

• Protocol:
  • 100 μg (1 μg/kg) human or ovine CRH IV bolus
  • Measure ACTH and cortisol at baseline, 15, 30, 45, 60, 90 minutes
• Interpretation:
  • "Cushing's Disease: Rise in ACTH > 35% or cortisol > 20% from baseline"
  • "Ectopic ACTH: Flat response (no rise)"
• Performance:
  • "Sensitivity: 85-95% for pituitary"
  • Useful in combination with HDDST [25]

C. Inferior Petrosal Sinus Sampling (IPSS) - GOLD STANDARD:

• Indication:
  • Differentiate pituitary from ectopic ACTH when peripheral tests inconclusive
  • Negative or equivocal pituitary MRI
  • RECOMMENDED before pituitary surgery when biochemistry atypical
• Procedure:
  • Simultaneous bilateral catheterization of inferior petrosal sinuses (IPS) draining pituitary
  • Peripheral venous sample for comparison
  • CRH stimulation (100 μg IV) to enhance gradient
• Interpretation:
  • "Baseline: IPS:Peripheral ACTH ratio > 2:1 → Pituitary source"
  • "Post-CRH (10-15 min): IPS:Peripheral ratio > 3:1 → Pituitary source"
  • "Lateralization: Inter-IPS gradient > 1.4 suggests tumor side (60-70% accurate)"
• Performance:
  • "Sensitivity: 95-98%"
  • "Specificity: 95-100%"
• Complications:
  • Venous thrombosis (less than 1%)
  • Brainstem infarction (rare, less than 0.5%)
  • Requires experienced interventional radiologist [26,27]

Imaging Studies

Pituitary MRI:

• Protocol: Dedicated pituitary MRI with gadolinium, thin cuts (1-2 mm)
• Findings in Cushing's Disease:
  • "Microadenoma (less than 10 mm): 85-90% of cases"
    • Hypointense on T1, variable on T2
    • Delayed enhancement compared to normal gland
  • "Macroadenoma (≥10 mm): 10-15%"
• Sensitivity: 50-60% (many microadenomas not visible)
• Pitfall: 10% of normal population has incidental pituitary "lesions"
• Interpretation: Positive MRI supports pituitary disease but does NOT confirm it; IPSS may still be needed [17]

Adrenal CT:

• Indication: When ACTH is suppressed (adrenal Cushing's)
• Protocol: Non-contrast and contrast-enhanced CT
• Findings:
  • "Adenoma: Well-defined, round, homogeneous, less than 6 cm, low attenuation (less than 10 HU unenhanced suggests benign lipid-rich adenoma)"
  • "Carcinoma: Large (> 6 cm), irregular, heterogeneous, calcifications, invasion, metastases"
  • Suppressed ACTH causes contralateral adrenal atrophy
• Additional: Adrenal washout protocol can characterize lesions [28]

Ectopic Source Localization: When ectopic ACTH suspected:

• High-resolution chest CT: Bronchial carcinoid, small cell lung cancer, thymic tumors
• Octreotide scintigraphy (111In-pentetreotide): Whole-body imaging for neuroendocrine tumors expressing somatostatin receptors
• 68Ga-DOTATATE PET/CT: Superior to octreotide scan, now preferred modality
• Neck-to-pelvis CT: Comprehensive search for occult tumors
• FDG-PET/CT: For aggressive malignancies (small cell lung cancer)
• 10-20% of ectopic sources remain occult despite extensive imaging [8,9]

Additional Laboratory Tests

Baseline Biochemistry:

• Electrolytes: Hypokalaemia, metabolic alkalosis (especially ectopic ACTH)
• Glucose: Fasting glucose, HbA1c (screen for diabetes)
• Lipid profile: Dyslipidemia common
• Bone profile: Calcium (normal or low), phosphate, alkaline phosphatase (high bone turnover)

Bone Density:

• DEXA scan: Assess osteoporosis risk; lumbar spine and hip
• High fracture risk even with osteopenia (bone quality impaired)

Ancillary Tests to Differentiate Pseudo-Cushing's:

• Combined dexamethasone-CRH test:
  • Dexamethasone 0.5 mg q6h × 48h, then CRH stimulation
  • Cortisol less than 38 nmol/L rules out Cushing's
• Midnight serum cortisol: > 207 nmol/L (7.5 μg/dL) suggests true Cushing's [11]

---

7. Management

Management goals: (1) Normalize cortisol excess, (2) Treat underlying cause, (3) Manage complications, (4) Minimize treatment-related morbidity. Approach is etiology-specific. [29,30]

Management Algorithm

CONFIRMED CUSHING'S SYNDROME
            ↓
       CHECK ACTH
    ┌──────┴──────┐
SUPPRESSED      ELEVATED
(Adrenal)    (ACTH-dependent)
    ↓               ↓
CT ADRENALS     MRI PITUITARY
    ↓               ↓
    ├─ Adenoma → Laparoscopic Adrenalectomy
    ├─ Carcinoma → Open Adrenalectomy ± Mitotane
    └─ Bilateral → Bilateral Adrenalectomy
                    ↓
            ┌───────┴────────┐
      MICROADENOMA      NEGATIVE/MACROADENOMA
            ↓                   ↓
    TRANSSPHENOIDAL          IPSS
       SURGERY                ↓
            ↓            ┌────┴────┐
       REMISSION?    CENTRAL   PERIPHERAL
        ↓     ↓          ↓         ↓
       YES    NO      TSS     ECTOPIC SEARCH
              ↓                    ↓
         ┌────┴─────┐         TUMOR RESECTION
    REPEAT TSS  RADIOTHERAPY   (if resectable)
         ↓          ↓              ↓
      FAILED?   FAILED?      MEDICAL THERAPY
         └──────┬──────┘       (if unresectable)
                ↓
         BILATERAL ADRENALECTOMY
         (definitive cure)
                ↓
         LIFELONG REPLACEMENT
         (Risk of Nelson's)

Cushing's Disease (Pituitary) Management

First-line: Transsphenoidal Surgery (TSS):

• Procedure: Endoscopic or microscopic approach via sphenoid sinus to selectively resect adenoma
• Success rates:
  • "Microadenomas: 80-90% remission"
  • "Macroadenomas: 50-65% remission"
  • Experienced pituitary surgeon essential (volume-outcome relationship) [31,32]
• Remission criteria: Morning cortisol less than 140 nmol/L on day 1-7 post-op (indicates complete tumor resection)
• Recurrence: 10-20% at 5 years, 25-30% at 10 years
• Complications:
  • "Diabetes insipidus: Transient 10-30%, permanent 2-5%"
  • "Hypopituitarism: 10-30% (may recover over months)"
  • "CSF leak: 2-5%"
  • "Meningitis: less than 2%"
  • "Vascular injury: less than 1%"

Post-operative Management:

• Immediate: Hydrocortisone replacement (contralateral suppression)
  • Start 10-20 mg AM, 5-10 mg PM
  • Continue until HPA axis recovery (months to years)
• Assessment:
  • Morning cortisol off hydrocortisone 24h to assess recovery
  • Synacthen test when cortisol 100-400 nmol/L
• Other deficiencies: Screen TSH, LH/FSH, GH, prolactin at 6-12 weeks

Second-line Options for Persistent/Recurrent Disease:

1. Repeat TSS:

   • Success: 50-70% if residual adenoma identified on MRI
   • Higher risk of hypopituitarism

2. Pituitary Radiotherapy:

   • Indications: Failed surgery, unsuitable for surgery, residual tumor
   • Modalities:
     • Conventional fractionated radiotherapy: 45-50 Gy over 5 weeks
     • Stereotactic radiosurgery (Gamma Knife): Single session, 15-25 Gy
   • Efficacy: Remission in 50-60% by 5 years, 70-80% by 10 years (delayed effect)
   • Complications:
     • Hypopituitarism: 50-80% (progressive over years)
     • Optic neuropathy: less than 2% (stereotactic)
     • Secondary tumors: Rare, long latency [33]
   • Bridge therapy: Medical therapy needed during the lag period

3. Medical Therapy (see below)

4. Bilateral Adrenalectomy:

   • Indication: Failed all other therapies, severe disease
   • Efficacy: 100% cure of hypercortisolism
   • Consequence: Lifelong glucocorticoid and mineralocorticoid replacement
   • Risk: Nelson's syndrome in 15-30% (see Complications)

Adrenal Cushing's Management

Unilateral Adrenal Adenoma:

• Treatment: Laparoscopic adrenalectomy (curative)
• Pre-operative: Consider medical therapy (ketoconazole, metyrapone) to normalize cortisol for 4-8 weeks → reduces surgical complications
• Outcomes: > 95% cure rate
• Post-operative:
  • Hydrocortisone replacement (contralateral adrenal suppressed)
  • "Median recovery time: 6-36 months"
  • Monitor for recovery with morning cortisol and Synacthen testing [28]

Adrenal Carcinoma:

• Surgical: Open adrenalectomy with complete resection (R0 resection goal)
  • En bloc resection if local invasion
  • Lymph node dissection controversial
• Adjuvant Therapy:
  • "Mitotane: Adrenolytic agent, improves recurrence-free survival"
    • Target level: 14-20 mg/L
    • Significant toxicity: GI upset, neurotoxicity, hepatotoxicity
  • "Chemotherapy: EDP-M regimen (etoposide, doxorubicin, cisplatin, mitotane) for advanced disease"
  • "Radiotherapy: Adjuvant RT to tumor bed controversial; for palliation of metastases"
• Prognosis:
  • "Stage I-II (localized): 60-80% 5-year survival"
  • "Stage III-IV (advanced): 10-20% 5-year survival [34]"

Bilateral Adrenal Hyperplasia:

• Rare cause; investigate for ACTH-independent macronodular adrenal hyperplasia (AIMAH) or primary pigmented nodular adrenocortical disease (PPNAD)
• Treatment: Bilateral adrenalectomy if medical therapy fails

Ectopic ACTH Syndrome Management

Tumor Resection (if localized and resectable):

• Bronchial carcinoid: Surgical resection curative
• Small cell lung cancer: Usually advanced; chemotherapy primary treatment
• Other NETs: Surgical resection when feasible

Medical Therapy (if unresectable or occult source):

• Block cortisol synthesis (see below)
• Tumor-directed therapy: Chemotherapy for SCLC, somatostatin analogs for carcinoids

Bilateral Adrenalectomy:

• Considered when tumor unresectable/occult AND severe hypercortisolism refractory to medical therapy
• Controls hypercortisolism while treating underlying malignancy

Medical Therapy for Hypercortisolism

Medical therapy used as:

• Bridge to surgery or while awaiting radiotherapy effect
• Primary treatment when surgery not feasible
• Adjunct for persistent disease post-surgery

Steroidogenesis Inhibitors (adrenal-directed):

1. Metyrapone:

   • Mechanism: Inhibits 11β-hydroxylase (final cortisol synthesis step)
   • Dosing: 250-500 mg TID-QID, titrate to UFC normal
   • Efficacy: Normalizes cortisol in 50-75%
   • Adverse effects: Hirsutism (androgen accumulation), hypertension (DOC accumulation), GI upset
   • Monitoring: UFC, ACTH, potassium, androgens [35]

2. Ketoconazole:

   • Mechanism: Inhibits multiple CYP enzymes (11β-hydroxylase, 17α-hydroxylase, cholesterol side-chain cleavage)
   • Dosing: 200-400 mg BID-TID
   • Efficacy: Normalizes cortisol in 50-70%
   • Adverse effects: Hepatotoxicity (monitor LFTs), GI upset, gynecomastia, reduced testosterone
   • Contraindications: Liver disease, concomitant QT-prolonging drugs
   • Monitoring: LFTs every 2 weeks initially, then monthly [36]

3. Osilodrostat (newer agent):

   • Mechanism: Potent 11β-hydroxylase inhibitor
   • Dosing: 1-7 mg BID
   • Efficacy: Normalizes UFC in 70-80% (superior to older agents)
   • Adverse effects: Adrenal insufficiency, hypokalemia, hypertension, QT prolongation
   • FDA approved 2020 for Cushing's disease [37]

4. Etomidate:

   • Mechanism: Inhibits 11β-hydroxylase
   • Route: IV infusion (requires ICU)
   • Indication: Severe, life-threatening Cushing's (Cushing's crisis)
   • Dosing: 0.03-0.1 mg/kg/h
   • Monitoring: Frequent cortisol levels (risk of acute adrenal insufficiency)

Pituitary-Directed Therapy:

1. Pasireotide:

   • Mechanism: Somatostatin analog (pan-somatostatin receptor agonist, especially SSTR5)
   • Indication: Cushing's disease (persistent/recurrent post-TSS or not surgical candidate)
   • Dosing:
     • SC: 600-900 μg BID
     • LAR: 10-40 mg IM monthly
   • Efficacy: Normalizes UFC in 25-35%
   • Adverse effects: Hyperglycemia (70-80%, often severe), GI upset, cholelithiasis, hypocortisolism
   • Monitoring: Glucose (may need diabetes therapy), UFC, pituitary MRI [38]

2. Cabergoline:

   • Mechanism: Dopamine D2 receptor agonist
   • Efficacy: Limited (15-40% response), often used as adjunct
   • Dosing: 0.5-3.5 mg/week

Glucocorticoid Receptor Antagonist:

1. Mifepristone:
   • Mechanism: Competitive GR antagonist (blocks cortisol action)
   • Indication: Cushing's syndrome with glucose intolerance/diabetes
   • Dosing: 300-1200 mg daily
   • Efficacy: Improves glucose control and Cushing's symptoms
   • Adverse effects: Hypokalemia, endometrial hyperplasia, adrenal insufficiency (cannot monitor with cortisol)
   • Monitoring: Clinical assessment, ACTH (rises markedly), potassium, endometrial ultrasound [39]

Combination Therapy:

• Often more effective than monotherapy
• Example: Metyrapone + ketoconazole or cabergoline
• Allows lower doses, reducing individual drug toxicity

Management of Complications and Comorbidities

Cardiovascular:

• Hypertension: Treat aggressively; often requires multiple agents (ACEi/ARB, CCB, thiazide)
• Thromboprophylaxis: Consider in hospitalized patients (high VTE risk)

Metabolic:

• Diabetes: May require insulin; improves with cortisol normalization
• Dyslipidemia: Statin therapy as per guidelines

Skeletal:

• Osteoporosis:
  • Bisphosphonates (zoledronic acid, alendronate) if T-score < -2.5 or prior fracture
  • Calcium (1200-1500 mg/day) and vitamin D (800-1000 IU/day) supplementation
  • Vertebroplasty/kyphoplasty for symptomatic vertebral fractures

Psychiatric:

• Depression/anxiety: May require antidepressants; often improves with cortisol normalization
• Psychosis: Antipsychotics; urgent cortisol reduction needed

Infectious:

• Prophylaxis: Consider PJP prophylaxis (trimethoprim-sulfamethoxazole) if severe hypercortisolism
• Vaccinations: Avoid live vaccines; inactivated vaccines may have reduced efficacy

Follow-up and Monitoring

Post-remission:

• Recurrence surveillance: Annual UFC and ONDST for life (pituitary disease)
• Pituitary function: Assess other axes at 3, 6, 12 months, then annually
• MRI surveillance: Pituitary MRI at 6-12 months, then annually for 5 years (then less frequent)
• Bone density: DEXA at 1-2 years post-remission, then per osteoporosis guidelines
• Cardiovascular risk: Manage residual hypertension, diabetes, dyslipidemia aggressively
• Quality of life: Persistent fatigue, cognitive issues, mood disturbance common; supportive care, rehabilitation

Active disease on medical therapy:

• UFC: Monthly until stable, then every 3-6 months
• Electrolytes: Monthly (hypokalemia risk)
• LFTs: Every 2 weeks × 2 months (ketoconazole), then monthly
• Glucose: HbA1c every 3 months (pasireotide)
• Drug levels: Mitotane levels every 4-6 weeks until therapeutic

---

8. Complications

Nelson's Syndrome

Definition: Enlargement of pre-existing corticotroph adenoma following bilateral adrenalectomy for Cushing's disease, with markedly elevated ACTH. [40,41]

Incidence:

• Historical (no prophylactic radiotherapy): 20-30%
• Modern (with pituitary radiotherapy): 5-10%

Pathophysiology:

• Loss of cortisol negative feedback → unrestrained ACTH hypersecretion
• Tumor expansion (macroadenoma development)

Clinical Features:

• Hyperpigmentation: Skin darkening (MSH activity from high ACTH), especially palmar creases, buccal mucosa
• Visual field defects: Bitemporal hemianopia from chiasmal compression
• Headaches: Mass effect
• Hypopituitarism: Other pituitary hormone deficiencies from tumor compression

Diagnosis:

• Markedly elevated ACTH (> 200 pmol/L or > 1000 pg/mL)
• Pituitary MRI: Macroadenoma, often with suprasellar extension

Prevention:

• Prophylactic pituitary radiotherapy after bilateral adrenalectomy (reduces risk but does not eliminate)

Treatment:

• TSS (debulking or resection)
• Radiotherapy (if surgery incomplete or not feasible)
• Temozolomide (chemotherapy for aggressive tumors)

Cardiovascular Complications

Acute:

• Myocardial infarction
• Stroke
• Venous thromboembolism (2-3× increased risk) [19]

Chronic:

• Accelerated atherosclerosis
• Left ventricular hypertrophy and cardiomyopathy
• Persistent hypertension (may not fully resolve even after remission)

Mortality:

• Cardiovascular disease is the leading cause of death in Cushing's syndrome
• Standardized mortality ratio: 1.8-4.8 (varies by cause and duration) [6,7]
• Residual cardiovascular risk persists for years after remission

Skeletal Complications

Osteoporosis and Fractures:

• Vertebral fractures: 30-50% at diagnosis
• Hip fractures: Increased risk
• Rapid bone loss: Can occur within months of hypercortisolism onset
• Recovery: Bone density improves slowly over years after remission; fracture risk may remain elevated [20]

Avascular Necrosis:

• Femoral head most common
• Humeral head, knee also affected
• Risk factors: High cortisol levels, exogenous steroid use
• May require arthroplasty

Metabolic Complications

Diabetes Mellitus:

• Present in 20-47% at diagnosis
• May require insulin therapy
• Improves with cortisol normalization but may not fully resolve

Dyslipidemia:

• Elevated triglycerides, LDL; reduced HDL
• Increases cardiovascular risk

Infectious Complications

Increased Susceptibility:

• Bacterial: Pneumonia, UTIs, skin infections
• Fungal: Candidiasis (oral, esophageal), invasive aspergillosis
• Opportunistic: Pneumocystis jirovecii pneumonia (in severe cases)
• Viral: Reactivation of latent infections (HSV, VZV)

Post-operative Infections:

• Surgical site infections
• Delayed wound healing

Psychiatric and Cognitive Complications

Acute:

• Steroid psychosis (hallucinations, delusions)
• Severe depression with suicidal ideation
• Acute mania

Chronic:

• Persistent cognitive impairment (memory, executive function)
• Mood disorders (depression, anxiety) may persist after remission
• Reduced quality of life [42]

Pregnancy Complications

Cushing's syndrome in pregnancy (rare):

• Maternal: Hypertension, preeclampsia, gestational diabetes, infection
• Fetal: Intrauterine growth restriction, prematurity, stillbirth
• Management: Metyrapone preferred; ketoconazole contraindicated

Post-remission Issues

Adrenal Insufficiency:

• HPA axis suppression post-surgery
• Recovery: 6-36 months (median 12-18 months)
• Requires hydrocortisone replacement and sick-day rules
• Risk of adrenal crisis if replacement inadequate

Hypopituitarism:

• After TSS or radiotherapy
• May be transient or permanent
• Requires hormone replacement (thyroxine, testosterone/estrogen, growth hormone)

Persistent Symptoms:

• Fatigue, reduced energy
• Cognitive issues (concentration, memory)
• Joint pains, myalgias
• Mood disturbance
• Quality of life significantly impaired even years after remission [42,43]

---

9. Prognosis and Outcomes

Untreated Disease

Mortality:

• 5-year mortality: 50%
• Causes: Cardiovascular events (MI, stroke), infections, suicide

Morbidity:

• Progressive complications (diabetes, osteoporosis, infections)
• Severe quality of life impairment

Treated Disease - Remission Rates

Cushing's Disease:

• Initial remission (TSS): 70-90% (microadenomas), 50-65% (macroadenomas)
• Recurrence at 10 years: 25-30%
• Long-term remission with radiotherapy: 70-80% by 10 years [31,32,33]

Adrenal Adenoma:

• Surgical cure: > 95%
• Recurrence: Rare (less than 5%)

Adrenal Carcinoma:

• 5-year survival:
  • "Stage I-II: 60-80%"
  • "Stage III-IV: 10-20%"
• High recurrence rate even after R0 resection [34]

Ectopic ACTH:

• Prognosis driven by underlying malignancy
• Bronchial carcinoid (resectable): Good prognosis, often cured
• Small cell lung cancer: Poor prognosis (median survival 6-12 months)

Mortality After Treatment

Standardized Mortality Ratio (SMR):

• Overall: 1.8-4.8 (depending on etiology and duration)
• Cushing's Disease: SMR 2.0-3.7
• Adrenal causes: SMR 1.8-2.5
• Ectopic ACTH: SMR 5-10 (reflects underlying malignancy) [6,7]

Causes of Death (in remission):

• Cardiovascular disease (40-50%): MI, stroke, heart failure
• Infections (10-15%)
• Malignancy (10%)
• Suicide (5%)

Excess Mortality Persists for Years: Cardiovascular risk remains elevated even after biochemical remission, likely due to irreversible vascular damage.

Quality of Life Outcomes

Physical Function:

• Improvement in most physical symptoms over 1-2 years
• Persistent issues: Fatigue (50%), arthralgia/myalgia (40%)

Metabolic:

• Diabetes: Improves in 50-70%, may persist in 30-50%
• Hypertension: Resolves in 50%, improves in 30%, persists in 20%
• Weight loss: Gradual over 1-2 years

Bone Health:

• Bone density improves slowly (5-10% over 2-3 years)
• Fracture risk remains elevated

Psychiatric and Cognitive:

• Depression improves in 60-70% but may persist
• Cognitive impairment may be irreversible in some patients
• Overall quality of life scores remain below general population [42,43]

Predictors of Outcome

Favorable Prognostic Factors:

• Microadenoma (vs. macroadenoma)
• Younger age
• Shorter disease duration
• Experienced pituitary surgeon (> 50 cases/year)
• Immediate post-operative cortisol less than 140 nmol/L (predicts remission)

Poor Prognostic Factors:

• Macroadenoma with cavernous sinus invasion
• Long disease duration (> 5 years)
• Severe comorbidities at diagnosis (diabetes, advanced osteoporosis)
• Ectopic ACTH from aggressive malignancy
• Adrenal carcinoma stage III-IV

---

10. Evidence and Guidelines

Key International Guidelines

Landmark Evidence

Diagnostic Studies:

1. Nieman et al., J Clin Endocrinol Metab 2008 [1]:

   • Endocrine Society guideline establishing diagnostic algorithm
   • Recommendation: ≥2 abnormal screening tests to confirm hypercortisolism
   • Evidence level: Expert consensus with moderate-quality evidence

2. Savas et al., J Clin Endocrinol Metab 2022 [22]:

   • Modern approach to diagnosis
   • Emphasizes late-night salivary cortisol as first-line screening
   • Addresses pitfalls and false positives

3. Vassiliadi et al., Endocrine 2021 [27]:

   • Systematic review of IPSS in Cushing's disease
   • Sensitivity 95-98%, specificity 95-100% for pituitary vs. ectopic
   • Complications rare in experienced centers

Epidemiology and Outcomes:

4. Hakami et al., Best Pract Res Clin Endocrinol Metab 2021 [4]:

   • Comprehensive epidemiology and mortality review
   • Incidence: 0.7-2.4/million/year
   • SMR: 1.8-4.8 depending on etiology

5. Pivonello et al., Lancet Diabetes Endocrinol 2016 [7]:

   • State-of-the-art complications review
   • Cardiovascular disease leading cause of death
   • Complications persist after remission

Surgical Outcomes:

6. Stroud et al., Pituitary 2020 [32]:

   • Systematic review and meta-analysis of TSS outcomes
   • Remission: 77% overall (85% microadenomas, 61% macroadenomas)
   • Recurrence: 10-20% at 5 years
   • Surgeon experience critical determinant

7. Brady et al., BMC Endocr Disord 2021 [31]:

   • Endoscopic TSS outcomes for Cushing's disease
   • Remission 78% at median 3.5 years follow-up
   • Complications: Transient DI 25%, permanent DI 2%, hypopituitarism 15%

Medical Therapy:

8. Fleseriu et al., Lancet Diabetes Endocrinol 2020 (Osilodrostat Phase III):

   • Osilodrostat normalized UFC in 72% vs. 8% placebo
   • Superior efficacy to older agents
   • FDA approved 2020

9. Tritos & Biller, Endocrinol Metab Clin North Am 2018 [36]:

   • Comprehensive review of medical therapies
   • Ketoconazole, metyrapone efficacy 50-75%
   • Combination therapy often needed

10. Castinetti, Arch Med Res 2023 [35]:

    • Updated pharmacological treatment review
    • Algorithm for selecting medical therapy based on etiology and severity

Nelson's Syndrome:

11. Reincke et al., Eur J Endocrinol 2021 [41]:
    • Systematic review of corticotroph tumor progression after bilateral adrenalectomy
    • Incidence 8-29% (median 21%)
    • Risk factors: Young age, MRI-visible tumor, time from bilateral adrenalectomy
    • Prophylactic radiotherapy reduces risk

Quality of Life:

12. Broersen et al., J Clin Endocrinol Metab 2019 [42]:

    • Persistent quality of life and cognitive impairment after treatment
    • QoL scores remain below general population
    • Cognitive deficits in memory and executive function persist

13. Puglisi et al., J Clin Endocrinol Metab 2024 [43]:

    • Long-term consequences systematic review
    • Cardiovascular risk persists for years after remission
    • Multidisciplinary long-term follow-up needed

Recent Advances:

14. Nieman et al., Nature Reviews Disease Primers 2025 [2]:

    • Comprehensive state-of-the-art review (most recent)
    • Updated pathophysiology, genetics, diagnostics
    • Precision medicine approaches emerging

15. Reincke & Fleseriu, JAMA 2023 [24]:

    • Clinical review for general audience
    • Practical diagnostic and management algorithms
    • Emphasis on multidisciplinary care

---

11. Patient and Layperson Explanation

What is Cushing's Syndrome?

Cushing's syndrome is a condition where your body has too much of a hormone called cortisol. Cortisol is often called the "stress hormone" because it helps your body respond to stress, but it also does many other important jobs like controlling blood sugar, blood pressure, and inflammation.

When you have too much cortisol for a long time, it causes problems throughout your body. It can make you gain weight (especially around your belly and face), weaken your muscles and bones, raise your blood sugar and blood pressure, and make your skin thin and bruise easily.

What Causes Cushing's Syndrome?

The most common cause is taking steroid medications (like prednisone or dexamethasone) for other health problems like asthma, arthritis, or autoimmune diseases. This is called "iatrogenic" Cushing's syndrome.

If your body is making too much cortisol on its own, it's usually because of a small, benign (non-cancerous) tumor:

• Pituitary gland (a pea-sized gland at the base of your brain): The tumor makes a hormone (ACTH) that tells your adrenal glands to make too much cortisol. This is called Cushing's Disease.
• Adrenal glands (small glands above your kidneys): The tumor directly makes too much cortisol.
• Ectopic tumors: Rarely, tumors in other parts of the body (like the lungs) can make ACTH and cause Cushing's syndrome.

What Are the Symptoms?

Common symptoms include:

• Weight gain: Mostly in your face (making it look round or "moon-shaped"), neck, and belly, while your arms and legs may stay thin
• Skin changes: Purple or red stretch marks (especially on your belly), easy bruising, slow healing of cuts
• Muscle weakness: Difficulty getting up from a chair or climbing stairs
• Bone problems: Weak bones that fracture easily
• High blood sugar: May develop diabetes
• High blood pressure
• Mood changes: Depression, anxiety, or mood swings
• For women: Irregular periods, excess facial hair

Not everyone has all these symptoms, and they develop slowly over months to years.

How is Cushing's Syndrome Diagnosed?

Because cortisol levels naturally go up and down throughout the day, diagnosing Cushing's syndrome can be tricky. Your doctor will likely do several tests:

1. 24-hour urine collection: You collect all your urine for a full day, and the lab measures cortisol levels.
2. Saliva test: You collect saliva late at night (around 11 PM) to check if your cortisol stays high when it should be low.
3. Dexamethasone suppression test: You take a pill at night, and your doctor checks your cortisol level the next morning. In healthy people, the pill lowers cortisol; in Cushing's syndrome, it doesn't.

If these tests show you have Cushing's syndrome, more tests help find the cause:

• Blood tests to measure ACTH (the hormone from the pituitary that controls cortisol)
• MRI scans of the pituitary or adrenal glands
• Sometimes, special tests like inferior petrosal sinus sampling (IPSS), where a doctor uses a thin tube to take blood samples from veins near the pituitary gland

How is Cushing's Syndrome Treated?

Treatment depends on the cause:

If you're taking steroid medications:

• Your doctor may slowly reduce the dose or switch to a different treatment for your underlying condition. Never stop steroids suddenly on your own—this can be dangerous.

If you have a pituitary tumor (Cushing's Disease):

• Surgery: The most common treatment is surgery through your nose (transsphenoidal surgery) to remove the tumor. This cures most people.
• Medications: If surgery doesn't work or isn't an option, medicines can block cortisol production or its effects.
• Radiation therapy: Sometimes used if surgery doesn't fully remove the tumor.

If you have an adrenal tumor:

• Surgery: Removing the affected adrenal gland usually cures Cushing's syndrome.

If the tumor is in another part of the body (ectopic):

• Treatment depends on the type and location of the tumor, often involving surgery to remove it or chemotherapy if it's cancer.

What Happens After Treatment?

After successful treatment, most symptoms improve over time, but recovery can take months to years:

• Weight and appearance: Slowly return to normal
• Muscle and bone strength: Gradually improve, but you may need treatment for osteoporosis
• Blood sugar and blood pressure: Often improve but may not completely normalize
• Energy and mood: May take a long time to feel like your old self

After surgery, you'll need to take steroid replacement medication for a while (sometimes months to years) because your body's own cortisol production needs time to recover.

What Should I Watch Out For?

If you've been treated for Cushing's syndrome:

• Follow up regularly with your doctor to check for recurrence
• Take steroid replacement as prescribed (if needed)
• Protect your bones (calcium, vitamin D, exercise)
• Manage blood pressure, blood sugar, and cholesterol
• Watch for signs of adrenal crisis if you're on steroid replacement (severe weakness, nausea, vomiting, low blood pressure)—this is a medical emergency

Living with Cushing's Syndrome

Cushing's syndrome can be challenging, both physically and emotionally. It's important to:

• Build a support system (family, friends, support groups)
• Be patient with recovery—it takes time
• Work closely with your endocrinologist and other specialists
• Ask questions and advocate for yourself

With proper treatment, most people with Cushing's syndrome can achieve remission and return to a good quality of life.

---

12. References

Primary Sources

1. Nieman LK, Biller BMK, Findling JW, et al. The Diagnosis of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2008;93(5):1526-1540. doi:10.1210/jc.2008-0125

2. Nieman LK, Castinetti F, Newell-Price J, et al. Cushing syndrome. Nat Rev Dis Primers. 2025;11(1):6. doi:10.1038/s41572-024-00588-w

3. Steffensen C, Bak AM, Rubeck KZ, Jørgensen JOL. Epidemiology of Cushing's syndrome. Neuroendocrinology. 2010;92(Suppl 1):1-5. doi:10.1159/000314297

4. Hakami OA, Ahmed S, Karavitaki N. Epidemiology and mortality of Cushing's syndrome. Best Pract Res Clin Endocrinol Metab. 2021;35(1):101521. doi:10.1016/j.beem.2021.101521

5. Gadelha M, Gatto F, Wildemberg LE, Fleseriu M. Cushing's syndrome. Lancet. 2023;402(10418):2237-2252. doi:10.1016/S0140-6736(23)01961-X

6. Pivonello R, Isidori AM, De Martino MC, et al. Complications of Cushing's syndrome: state of the art. Lancet Diabetes Endocrinol. 2016;4(7):611-629. doi:10.1016/S2213-8587(16)00086-3

7. Pivonello R, Isidori AM, De Martino MC, et al. Complications of Cushing's syndrome: state of the art. Lancet Diabetes Endocrinol. 2016;4(7):611-629. doi:10.1016/S2213-8587(16)00086-3

8. Ragnarsson O, Juhlin CC, Torpy DJ, Schrey S, Bensing S. A clinical perspective on ectopic Cushing's syndrome. Trends Endocrinol Metab. 2024;35(4):306-317. doi:10.1016/j.tem.2023.12.003

9. Gamrat-Żmuda A, Minasyan M, Wysocki PJ, et al. Ectopic Cushing's Syndrome in Advanced Small-Cell Lung Cancer (SCLC): Clinical Challenges and Therapeutic Opportunities. Cancers (Basel). 2025;17(10):1611. doi:10.3390/cancers17101611

10. Findling JW, Raff H. Recognition of Nonneoplastic Hypercortisolism in the Evaluation of Patients With Cushing Syndrome. J Endocr Soc. 2023;7(7):bvad087. doi:10.1210/jendso/bvad087

11. Ceccato F, Boscaro M. Cushing's Syndrome: Screening and Diagnosis. High Blood Press Cardiovasc Prev. 2016;23(3):209-215. doi:10.1007/s40292-016-0153-4

12. Ferriere A, Tabarin A. Cushing's syndrome: Treatment and new therapeutic approaches. Best Pract Res Clin Endocrinol Metab. 2020;34(2):101381. doi:10.1016/j.beem.2020.101381

13. Nowak E, Vogel F, Albani A, et al. Diagnostic challenges in cyclic Cushing's syndrome: a systematic review. Lancet Diabetes Endocrinol. 2023;11(8):593-605. doi:10.1016/S2213-8587(23)00150-X

14. Nowak E, Vogel F, Albani A, et al. Diagnostic challenges in cyclic Cushing's syndrome: a systematic review. Lancet Diabetes Endocrinol. 2023;11(8):593-605. doi:10.1016/S2213-8587(23)00150-X

15. Prete A, Bancos I. Mild autonomous cortisol secretion: pathophysiology, comorbidities and management approaches. Nat Rev Endocrinol. 2024;20(8):460-473. doi:10.1038/s41574-024-00984-y

16. Reincke M, Sbiera S, Hayakawa A, et al. Mutations in the deubiquitinase gene USP8 cause Cushing's disease. Nat Genet. 2015;47(1):31-38. doi:10.1038/ng.3166

17. Fleseriu M, Auchus R, Bancos I, et al. Consensus on diagnosis and management of Cushing's disease: a guideline update. Lancet Diabetes Endocrinol. 2021;9(12):847-875. doi:10.1016/S2213-8587(21)00235-7

18. Fassnacht M, Tsagarakis S, Terzolo M, et al. European Society of Endocrinology clinical practice guidelines on the management of adrenal incidentalomas, in collaboration with the European Network for the Study of Adrenal Tumors. Eur J Endocrinol. 2023;189(1):G1-G42. doi:10.1093/ejendo/lvad066

19. Isand K, Feelders R, Brue T, et al. High prevalence of venous thrombotic events in Cushing's syndrome: data from ERCUSYN and details in 618 patients. Eur J Endocrinol. 2024;190(1):93-101. doi:10.1093/ejendo/lvad176

20. Puglisi S, Perini AME, Botto C, et al. Long-Term Consequences of Cushing Syndrome: A Systematic Literature Review. J Clin Endocrinol Metab. 2024;109(3):e1642-e1655. doi:10.1210/clinem/dgad453

21. Pivonello R, Isidori AM, De Martino MC, et al. Complications of Cushing's syndrome: state of the art. Lancet Diabetes Endocrinol. 2016;4(7):611-629. doi:10.1016/S2213-8587(16)00086-3

22. Savas M, Mehta S, Agrawal N, Feelders RA, Dutta P. Approach to the Patient: Diagnosis of Cushing Syndrome. J Clin Endocrinol Metab. 2022;107(12):3162-3174. doi:10.1210/clinem/dgac492

23. Balomenaki M, Margaritopoulos D, Vassiliadi DA, Tsagarakis S. Diagnostic workup of Cushing's syndrome. J Neuroendocrinol. 2022;34(8):e13111. doi:10.1111/jne.13111

24. Reincke M, Fleseriu M. Cushing Syndrome: A Review. JAMA. 2023;330(2):170-181. doi:10.1001/jama.2023.11305

25. Findling JW, Raff H. Diagnosis of endocrine disease: Differentiation of pathologic/neoplastic hypercortisolism (Cushing's syndrome) from physiologic/non-neoplastic hypercortisolism (formerly known as pseudo-Cushing's syndrome). Eur J Endocrinol. 2017;176(5):R205-R216. doi:10.1530/EJE-16-0946

26. Vassiliadi DA, Mourelatos P, Kratimenos T, et al. Inferior petrosal sinus sampling in Cushing's syndrome: usefulness and pitfalls. Endocrine. 2021;73(3):552-562. doi:10.1007/s12020-021-02764-4

27. Vassiliadi DA, Mourelatos P, Kratimenos T, et al. Inferior petrosal sinus sampling in Cushing's syndrome: usefulness and pitfalls. Endocrine. 2021;73(3):552-562. doi:10.1007/s12020-021-02764-4

28. Fassnacht M, Tsagarakis S, Terzolo M, et al. European Society of Endocrinology clinical practice guidelines on the management of adrenal incidentalomas. Eur J Endocrinol. 2023;189(1):G1-G42. doi:10.1093/ejendo/lvad066

29. Nieman LK, Biller BMK, Findling JW, et al. Treatment of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2015;100(8):2807-2831. doi:10.1210/jc.2015-1818

30. Ferriere A, Tabarin A. Cushing's syndrome: Treatment and new therapeutic approaches. Best Pract Res Clin Endocrinol Metab. 2020;34(2):101381. doi:10.1016/j.beem.2020.101381

31. Brady Z, Garrahy A, Carthy C, et al. Outcomes of endoscopic transsphenoidal surgery for Cushing's disease. BMC Endocr Disord. 2021;21(1):36. doi:10.1186/s12902-021-00679-9

32. Stroud A, Dhaliwal P, Alvarado R, et al. Outcomes of pituitary surgery for Cushing's disease: a systematic review and meta-analysis. Pituitary. 2020;23(5):595-609. doi:10.1007/s11102-020-01066-8

33. Albani A, Theodoropoulou M. Persistent Cushing's Disease after Transsphenoidal Surgery: Challenges and Solutions. Exp Clin Endocrinol Diabetes. 2021;129(3):168-176. doi:10.1055/a-1220-6056

34. Fassnacht M, Dekkers OM, Else T, et al. European Society of Endocrinology Clinical Practice Guidelines on the management of adrenocortical carcinoma in adults. Eur J Endocrinol. 2018;179(4):G1-G46. doi:10.1530/EJE-18-0608

35. Castinetti F. Pharmacological Treatment of Cushing's Syndrome. Arch Med Res. 2023;54(8):102908. doi:10.1016/j.arcmed.2023.102908

36. Tritos NA, Biller BMK. Medical Therapy for Cushing's Syndrome in the Twenty-first Century. Endocrinol Metab Clin North Am. 2018;47(2):427-440. doi:10.1016/j.ecl.2018.01.006

37. Fleseriu M, Pivonello R, Young J, et al. Osilodrostat, a potent oral 11β-hydroxylase inhibitor: 22-week, prospective, Phase II study in Cushing's disease. Pituitary. 2016;19(2):138-148. doi:10.1007/s11102-015-0692-z

38. Lacroix A, Gu F, Gallardo W, et al. Efficacy and safety of once-monthly pasireotide in Cushing's disease: a 12 month clinical trial. Lancet Diabetes Endocrinol. 2018;6(1):17-26. doi:10.1016/S2213-8587(17)30326-1

39. Fleseriu M, Biller BMK, Findling JW, et al. Mifepristone, a glucocorticoid receptor antagonist, produces clinical and metabolic benefits in patients with Cushing's syndrome. J Clin Endocrinol Metab. 2012;97(6):2039-2049. doi:10.1210/jc.2011-3350

40. Fountas A, Karavitaki N. Nelson's Syndrome: An Update. Endocrinol Metab Clin North Am. 2020;49(3):413-432. doi:10.1016/j.ecl.2020.05.004

41. Reincke M, Albani A, Assie G, et al. Corticotroph tumor progression after bilateral adrenalectomy (Nelson's syndrome): systematic review and expert consensus recommendations. Eur J Endocrinol. 2021;184(3):R73-R85. doi:10.1530/EJE-20-1088

42. Broersen LHA, Andela CD, Dekkers OM, et al. Improvement but No Normalization of Quality of Life and Cognitive Functioning After Treatment of Cushing Syndrome. J Clin Endocrinol Metab. 2019;104(11):5325-5337. doi:10.1210/jc.2019-01054

43. Puglisi S, Perini AME, Botto C, et al. Long-Term Consequences of Cushing Syndrome: A Systematic Literature Review. J Clin Endocrinol Metab. 2024;109(3):e1642-e1655. doi:10.1210/clinem/dgad453

44. Fassnacht M, Tsagarakis S, Terzolo M, et al. European Society of Endocrinology clinical practice guidelines on the management of adrenal incidentalomas. Eur J Endocrinol. 2023;189(1):G1-G42. doi:10.1093/ejendo/lvad066

---

13. Examination Focus

High-Yield Exam Topics

Diagnosis and Investigation:

1. Screening tests interpretation:

   • Knowing when to suspect Cushing's (discriminatory features)
   • Requirement for ≥2 positive screening tests
   • Pitfalls causing false positives/negatives

2. ACTH-dependent vs. independent differentiation:

   • ACTH level interpretation
   • High-dose dexamethasone suppression test
   • IPSS indications and interpretation

3. Imaging:

   • Pituitary MRI sensitivity limitations
   • Adrenal CT findings differentiating adenoma vs. carcinoma
   • Ectopic source localization strategies

Classification and Etiology: 4. Cushing's Disease vs. Syndrome: Most common exam trap—know the distinction 5. Ectopic ACTH phenotype: Rapid onset, cachexia, severe hypokalaemia, hyperpigmentation 6. Pseudo-Cushing's states: Alcohol, depression, physiological stress

Management: 7. Transsphenoidal surgery: First-line for Cushing's disease; remission criteria 8. Medical therapy indications: Pre-operative optimization, persistent disease 9. Nelson's syndrome: Pathophysiology, prevention, management

Complications: 10. Cardiovascular: Leading cause of death; SMR 1.8-4.8 11. Osteoporosis: Rapid onset; vertebral fractures common 12. Hypercoagulability: VTE risk 2-3× increased

Common MRCP/FRACP Questions

MCQ Stems:

1. Q: A 35-year-old woman with centripetal obesity, proximal myopathy, and wide purple abdominal striae. Overnight dexamethasone suppression test: cortisol 180 nmol/L. 24-hour UFC: 4× ULN. Plasma ACTH: 25 pmol/L. High-dose dexamethasone suppression test: 60% cortisol reduction. What is the most likely diagnosis?

   • A: Cushing's Disease (pituitary adenoma)
   • Rationale: Elevated ACTH (ACTH-dependent), suppression with high-dose dex (pituitary)

2. Q: A 60-year-old man with rapid-onset proximal weakness, weight loss, hyperpigmentation. Potassium 2.2 mmol/L. Plasma ACTH 150 pmol/L. High-dose dexamethasone suppression test: no suppression. What is the next best test?

   • A: CT chest (searching for ectopic ACTH source, likely small cell lung cancer or carcinoid)
   • Rationale: Ectopic ACTH phenotype; no suppression suggests ectopic source

3. Q: A 40-year-old woman undergoes bilateral adrenalectomy for Cushing's disease refractory to pituitary surgery and radiotherapy. Two years later, she develops progressive hyperpigmentation and bitemporal hemianopia. What is the diagnosis?

   • A: Nelson's syndrome
   • Rationale: Corticotroph tumor expansion post-bilateral adrenalectomy

4. Q: A patient with Cushing's syndrome has ACTH less than 1 pmol/L. CT abdomen shows a 4 cm right adrenal mass with HU less than 10 on unenhanced CT and rapid contrast washout. What is the most appropriate management?

   • A: Laparoscopic right adrenalectomy
   • Rationale: ACTH-independent (adrenal cause); imaging consistent with benign adenoma

5. Q: Which finding is MOST specific for Cushing's syndrome vs. simple obesity?

   • A: Wide (> 1 cm) purple striae
   • Rationale: Discriminatory feature; simple obesity causes pale striae

Viva Voce Scenarios

Viva 1: Diagnostic Approach

• Examiner: "A GP refers a patient with possible Cushing's syndrome. How would you confirm the diagnosis?"
• Key points:
  • Screen with ≥2 of 3 tests (UFC, LNSC, ONDST)
  • Rule out exogenous steroids and pseudo-Cushing's
  • If confirmed, measure ACTH to determine ACTH-dependent vs. independent
  • Localize source (pituitary MRI, high-dose dex, CRH test, IPSS if needed)

Viva 2: Management Decision

• Examiner: "A patient with Cushing's disease undergoes TSS. Post-op day 3 cortisol is 450 nmol/L. What does this mean and what is your management?"
• Key points:
  • Post-op cortisol > 140 nmol/L suggests persistent disease (incomplete resection)
  • "Options: Repeat TSS if residual tumor visible on MRI, radiotherapy, medical therapy, bilateral adrenalectomy"
  • Need to manage hypercortisolism while planning definitive therapy

Viva 3: Hyperpigmentation Mechanism

• Examiner: "Why do patients with ectopic ACTH develop hyperpigmentation but those with adrenal adenomas do not?"
• Key points:
  • ACTH is derived from POMC, which also produces MSH (melanocyte-stimulating hormone)
  • High ACTH (ectopic or pituitary) → MSH effect → hyperpigmentation
  • Adrenal adenomas suppress ACTH → no MSH → no hyperpigmentation

Viva 4: Nelson's Syndrome

• Examiner: "What is Nelson's syndrome and how can it be prevented?"
• Key points:
  • Enlargement of corticotroph adenoma after bilateral adrenalectomy
  • Loss of cortisol negative feedback → unrestrained ACTH → tumor growth
  • Presents with hyperpigmentation, visual field defects, headaches
  • "Prevention: Prophylactic pituitary radiotherapy reduces risk (but doesn't eliminate)"

OSCE Stations

History Taking:

• Patient presents with weight gain, easy bruising, mood changes
• Elicit discriminatory features (proximal myopathy, purple striae, facial plethora)
• Drug history: Exogenous steroids (often missed!)
• Screen for complications: Fractures, diabetes, hypertension, infections

Data Interpretation:

• Provide lab results and imaging; candidate must interpret and formulate management plan
• Common scenarios:
  • Discordant ACTH and imaging (e.g., suppressed ACTH but no adrenal mass → investigate exogenous sources)
  • Equivocal high-dose dex test → recommend IPSS

Examination:

• Cushing's stigmata on mannequin or standardized patient
• Identify moon facies, buffalo hump, striae, proximal myopathy
• Comment on discriminatory vs. non-discriminatory features

---

Medical Disclaimer: MedVellum content is for educational purposes and clinical reference. Clinical decisions should account for individual patient circumstances. Always consult appropriate specialists and current guidelines for patient management.